For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

Therapies for obesity and inhibitors for lipoprotein(a) (Lp[a]) are among those to be featured at the American Heart ...

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / ...

A study published in JAMA Psychiatry found that glucagon-like peptide 1 drugs such as semaglutide and liraglutide can ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

The U.S. Food and Drug Administration approved the drugs for weight loss in 2021. The drugs, called glucagon-like peptide-1 ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

GLP-1 Receptor Agonist medications, such as Ozempic, combined with exercise and nutrition, can help reduce obesity, according ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Structure Therapeutics (GPCR) announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS ...